Biotechnology
72 companies across the library’s three pools, one row each. The columns are the line items this kind of business is read on; each header names its basis, and the margins and returns are medians over each company’s readable record — the through-cycle level, never one year’s print. Rows open largest first by latest-year revenue, and every column sorts both ways — the re-ordering is the reader’s own act, and a sorted view keeps its order in the address bar. The company stays in view as the columns scroll. A dash is a figure that could not be read; n/a is one that does not apply to that member; both sit at the back of a sorted column.
From the latest filings · data as of July 9, 2026.
As a group: median revenue $106M; median gross margin 65.8%; median operating margin -243.7%; median owner earnings ($76M); median return on invested capital -44.7%; 54 of 72 hold net cash. Medians of this table’s own columns, over the members each applies to · data as of July 9, 2026.
| latest fiscal year, USD | median over the record | median over the record | op. cash − maintenance capex · latest FY, USD | after tax · median over the record | debt − cash & ST investments · latest FY, USD | ||||
|---|---|---|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | Biotechnology | $36.8B | 75.7% | 35.9% | $8.1B | 14.4% | $7.6B | |
| GILD | Gilead Sciences Inc. | Biotechnology | $29.4B | 78.8% | 28.0% | $9.5B | 15.2% | $25.9B | |
| BIIB | Biogen Inc. | Biotechnology | $9.9B | 80.8% | 33.8% | $2.1B | 18.3% | $1.7B | |
| IDXX | IDEXX Laboratories Inc. | Biotechnology | $4.3B | 58.0% | 25.7% | $1.1B | 56.1% | $519M | |
| BNTX | BioNTech SE American Depositary Share | Biotechnology | $3.3B | 84.3% | -42.2% | $457M | -10.8% | +$16.7B cash | |
| NBIX | Neurocrine | Biotechnology | $2.9B | 98.7% | 9.2% | $757M | 9.5% | +$1.1B cash | |
| QDEL | QuidelOrtho | Biotechnology | $2.7B | — | 4.6% | ($83M) | -15.7% | $2.7B | |
| EXEL | Exelixis Inc. | Biotechnology | $2.3B | 96.4% | 20.0% | $876M | 14.4% | +$870M cash | |
| QGEN | Qiagen N.V. | Biotechnology | $2.1B | 64.4% | 17.8% | $453M | 6.2% | $556M | |
| MRNA | Moderna Inc. | Biotechnology | $1.9B | 54.8% | -130.9% | ($2.1B) | -34.7% | +$2.0B cash | |
| LNTH | Lantheus Holdings | Biotechnology | $1.5B | 50.3% | 15.6% | $354M | 23.5% | $210M | |
| HALO | Halozyme | Biotechnology | $1.4B | 81.6% | 33.6% | $645M | 15.5% | $1.7B | |
| TECH | Bio-Techne | Biotechnology | $1.2B | 66.5% | 21.3% | $257M | 8.4% | $183M | |
| NVAX | Novavax Inc. | Biotechnology | $1.1B | 65.1% | -147.1% | ($250M) | -127.7% | +$491M cash | |
| NEOG | Neogen | Biotechnology | $895M | 46.9% | 15.8% | ($46M) | 8.4% | $765M | |
| BCRX | BioCryst Pharmaceuticals Inc. | Biotechnology | $875M | 95.5% | -184.4% | $346M | -141.8% | +$275M cash | |
| MYGN | Myriad Genetics Inc. | Biotechnology | $825M | 69.9% | -20.7% | ($44M) | -15.3% | +$30M cash | |
| RGEN | Repligen Corporation | Biotechnology | $738M | 54.9% | 13.4% | $94M | 3.9% | +$225M cash | |
| ALVO | Alvotech | Biotechnology | $586M | 22.8% | -388.1% | ($88M) | -68.1% | $1.1B | |
| ALVOW | Alvotech | Biotechnology | $586M | 22.8% | -388.1% | ($88M) | -68.1% | $1.1B | |
| ADMA | ADMA Biologics Inc | Biotechnology | $510M | -28.1% | -141.1% | $42M | -38.8% | $12M | |
| TARS | Tarsus Pharmaceuticals Inc. | Biotechnology | $451M | — | -65.9% | ($13M) | -47.3% | +$345M cash | |
| IMCR | Immunocore Holdings plc | Biotechnology | $400M | 99.4% | -23.9% | ($14M) | — | +$864M cash | |
| KRYS | Krystal Biotech | Biotechnology | $389M | — | 22.6% | $195M | -21.4% | +$492M cash | |
| TWST | Twist Bioscience Corporation | Biotechnology | $377M | 36.6% | -115.4% | ($76M) | -50.9% | +$231M cash | |
| ADPT | Adaptive Biotechnologies Corporation | Biotechnology | $277M | 68.1% | -108.0% | ($49M) | -31.7% | $61M | |
| VCEL | Vericel Corporation | Biotechnology | $276M | 67.2% | -5.1% | $40M | -3.7% | +$137M cash | |
| IOVA | Iovance Biotherapeutics Inc. | Biotechnology | $264M | 34.3% | -240.9% | ($336M) | -70.4% | +$288M cash | |
| VALN | Valneva SE | Biotechnology | $200M | 41.9% | -31.4% | ($66M) | -43.5% | $75M | |
| RGNX | REGENXBIO Inc. | Biotechnology | $170M | 59.7% | -280.0% | ($126M) | -49.5% | +$230M cash | |
| DNA | Ginkgo Bioworks Holdings Inc. | Biotechnology | $170M | — | -246.5% | ($179M) | -415.0% | +$423M cash | |
| MAZE | Maze Therapeutics Inc. | Biotechnology | $168M | — | — | ($113M) | — | +$342M cash | |
| BEAM | Beam Therapeutics Inc. | Biotechnology | $140M | — | -654.3% | ($360M) | -72.7% | +$1.2B cash | |
| GLUE | Monte Rosa Therapeutics Inc. | Biotechnology | $124M | — | — | ($27M) | — | +$130M cash | |
| IBRX | ImmunityBio Inc. | Biotechnology | $113M | 100.0% | -58239.5% | ($309M) | -60.2% | $82M | |
| IPSC | Century Therapeutics Inc. | Biotechnology | $109M | — | -2574.2% | ($105M) | -84.2% | +$107M cash | |
| STRO | Sutro Biopharma Inc. | Biotechnology | $102M | — | -154.5% | ($179M) | -54.7% | +$137M cash | |
| FDMT | 4D Molecular Therapeutics Inc. | Biotechnology | $85M | — | -544.6% | ($110M) | -41.1% | +$403M cash | |
| MGTX | MeiraGTx Holdings plc | Biotechnology | $81M | — | -438.4% | ($50M) | -134.1% | +$16M cash | |
| AUTL | Autolus Therapeutics PLC | Biotechnology | $75M | — | -2385.6% | ($292M) | — | +$104M cash | |
| ABCL | AbCellera Biologics Inc. | Biotechnology | $75M | — | -35.5% | ($174M) | -18.4% | +$129M cash | |
| RXRX | Recursion Pharmaceuticals Inc. | Biotechnology | $75M | 4.5% | -867.9% | ($378M) | -128.9% | +$734M cash | |
| CLLS | Cellectis S.A. | Biotechnology | $73M | 25.0% | -367.8% | ($42M) | -229.3% | +$73M cash | |
| CGEN | Compugen Ltd. | Biotechnology | $73M | 87.3% | -471.7% | $31M | -41.9% | +$100M cash | |
| VIR | Vir Biotechnology Inc. | Biotechnology | $69M | 98.9% | -791.3% | ($397M) | -44.7% | +$461M cash | |
| NTLA | Intellia Therapeutics Inc. | Biotechnology | $68M | 100.0% | -651.7% | ($396M) | -49.4% | +$450M cash | |
| MESO | Mesoblast Limited | Biotechnology | $65M | 100.0% | -727.6% | ($61M) | -11.2% | +$3M cash | |
| PLX | Protalix BioTherapeutics Inc. (DE) | Biotechnology | $53M | 57.4% | -27.3% | ($14M) | -13.0% | $14M | |
| FENC | Fennec Pharmaceuticals Inc. | Biotechnology | $45M | — | -60.1% | ($12M) | — | +$17M cash | |
| KYMR | Kymera Therapeutics Inc. | Biotechnology | $39M | 0.0% | -344.4% | ($234M) | -28.9% | +$357M cash | |
| CCCC | C4 Therapeutics Inc. | Biotechnology | $36M | — | -336.1% | ($99M) | -50.0% | +$308M cash | |
| XFOR | X4 Pharmaceuticals Inc. | Biotechnology | $35M | — | -1423.6% | ($86M) | -177.3% | +$142M cash | |
| RLAY | Relay Therapeutics Inc. | Biotechnology | $15M | — | -3722.1% | ($236M) | -46.6% | +$84M cash | |
| IPHA | Innate Pharma S.A. ADS | Biotechnology | $10M | — | -90.8% | ($61M) | -1025.6% | +$39M cash | |
| ACOG | Alpha Cognition Inc. | Biotechnology | $10M | — | — | ($20M) | — | +$65M cash | |
| TSHA | Taysha Gene Therapies Inc. | Biotechnology | $10M | — | -1130.6% | ($94M) | — | +$270M cash | |
| NNNN | Anbio Biotechnology | Biotechnology | $9M | 53.4% | 29.2% | — | 36.7% | +$12M cash | |
| SLDB | Solid Biosciences Inc. | Biotechnology | $8M | — | — | ($157M) | -154.0% | +$60M cash | |
| EVAX | Evaxion A/S American Depositary Share | Biotechnology | $8M | — | -440.6% | ($7M) | -1552.0% | +$9M cash | |
| FATE | Fate Therapeutics Inc. | Biotechnology | $7M | — | -943.1% | ($112M) | -57.6% | +$189M cash | |
| ABEO | Abeona Therapeutics Inc. | Biotechnology | $6M | — | -2686.3% | ($79M) | -88.6% | +$171M cash | |
| DBVT | DBV Technologies S.A. | Biotechnology | $6M | — | -1727.6% | ($122M) | -1205.9% | +$193M cash | |
| PRME | Prime Medicine Inc. | Biotechnology | $5M | — | -4498.1% | ($167M) | -176.8% | +$63M cash | |
| OCGN | Ocugen Inc. | Biotechnology | $4M | — | -1425.7% | ($57M) | — | $10M | |
| CGON | CG Oncology Inc. | Biotechnology | $4M | — | -10067.3% | ($132M) | — | +$739M cash | |
| CRSP | CRISPR Therapeutics AG | Biotechnology | $4M | — | -1319.3% | ($346M) | -32.0% | +$1.9B cash | |
| CLDX | Celldex Therapeutics Inc. | Biotechnology | $2M | 95.6% | -1958.7% | ($214M) | -45.6% | +$507M cash | |
| PLUR | Pluri Inc. | Biotechnology | $1M | — | -9493.4% | ($20M) | -68.3% | +$16M cash | |
| INBX | Inhibrx Biosciences Inc. | Biotechnology | $1M | — | -12178.9% | ($130M) | — | +$24M cash | |
| PROK | ProKidney Corp. | Biotechnology | $893K | — | — | ($127M) | — | +$109M cash | |
| LXEO | Lexeo Therapeutics Inc. | Biotechnology | $654K | — | — | ($99M) | — | +$150M cash | |
| CADL | Candel Therapeutics Inc. | Biotechnology | $125K | — | -20580.8% | ($39M) | — | +$118M cash |
Every figure is recomputed from the company’s own SEC or EDINET filings, the same way as on its page; the columns name facts, weigh nothing, and form no rank. Foreign filers are stated in US dollars at the dated reference rate (as of 2026-07-17) so each money column sorts on one basis; their own pages keep the records as filed. A foreign filer whose conversion terms are missing shows its money as filed and sorts to the back of the column — never a guessed conversion. Ratios and margins are currency-free.